Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Acts as a negative regulator of innate and adaptive immunity by maintaining immune homeostasis. Additionally we are shipping Tumor Necrosis Factor, alpha-Induced Protein 8-Like 2 Proteins (11) and many more products for this protein.
Showing 10 out of 55 products:
Human Polyclonal TNFAIP8L2 Primary Antibody for EIA, WB - ABIN955273
Zhang, Hao, Lou, Xi, Wang, Wang, Qu, Guo, Chen, Zhang, Liu: Tissue-specific expression of TIPE2 provides insights into its function. in Molecular immunology 2010
Human Polyclonal TNFAIP8L2 Primary Antibody for ELISA, WB - ABIN1450851
Sun, Gong, Carmody, Hilliard, Li, Sun, Kong, Xu, Hilliard, Hu, Shen, Yang, Chen: TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. in Cell 2008
the expression of TIPE2 protein could be a predictor of better prognosis for DLBCL.
Insufficient expression of TIPE2 might be involved in the hyperreactivity of monocyte to Toll (show TLR4 Antibodies)-like receptor ligands in primary biliary cirrhosis.
data provided the first evidence that TIPE2 inhibits gastric cancer cell migration, invasion and metastasis very probably via reversal of EMT (show ITK Antibodies), revealing that TIPE2 may be a novel therapeutic target for human gastric cancer EMT (show ITK Antibodies) and metastasis.
Authors demonstrated that TIPE2 overexpression may suppress proliferation, migration, and invasion in prostate cancer cells by inhibiting the PI3K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies) signaling pathway.
TIPE2 suppressed breast cancer tumorigenesis, growth and metastasis possibly via regulation of the AKT (show AKT1 Antibodies) and p38 (show CRK Antibodies) signaling pathways.
these data suggest that TIPE2 overexpression inhibited hypoxia-induced Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) pathway activation and EMT (show ITK Antibodies) in glioma cells.
this study shows that TIPE2 contributes to the pathogenesis of ankylosing spondylitis
TIPE2 expression was significantly decreased in human breast cancer tissue and cell lines. Overexpression of TIPE2 inhibited the proliferation in vitro and tumor xenograft growth in vivo. TIPE2 also inhibited the migration/invasion of breast cancer cells through preventing the epithelial-to-mesenchymal transition (EMT (show ITK Antibodies)) phenotype.
Low expression of TIPE2 is associated with hepatocellular carcinogenesis.
our data suggest a previously unappreciated role of TIPE2 in the crosstalk between skin SCC (show CYP11A1 Antibodies) and TAMs and highlight TIPE2 as a promising novel target for skin SCC (show CYP11A1 Antibodies) treatment.
Our current study shows that TIPE2-deficient bone-marrow cells are defective in IL-4 (show IL4 Antibodies) induced M2 macrophage differentiation in vitro. TIPE2 promotes phosphoinositide metabolism and the activation of the down-stream AKT (show AKT1 Antibodies) signaling pathway, which in turn leads to the expression of markers specific for M2 macrophages.
The present study demonstrates that TIPE2 acts as a novel negative regulator of inflammatory and immune responses through TAK1 (show NR2C2 Antibodies) signaling.
Data show that after tumor necrosis factor alpha-induced protein 8 like-2 (TIPE2) gene was down-regulated, the expression of the CD69 antigen (show CD69 Antibodies) was increased, and the proliferation of T lymphocytes and the secretion of cytokines IL-2 (show IL2 Antibodies) and IFN-gamma (show IFNG Antibodies) were enhanced.
TIPE2 alleviates experimental SLE through induction of macrophage polarization to a M2 phenotype, which may be used as a promising therapeutic strategy for treating SLE.
TIPE2 acts as a negative regulator linking NOD2 (show NOD2 Antibodies) and inflammatory responses.
TIPE2 plays a suppressive role in injury-induced restenosis and may serve as a new therapeutic target for treating the disease.
Tipe2 provides a molecular bridge between miR (show MLXIP Antibodies)-21 and cell apoptosis; miR (show MLXIP Antibodies)-21 suppresses apoptosis in activated T cells at least in part through directly targeting tumor suppressor gene Tipe2.
TIPE2 deficiency in hematopoietic cells ameliorates experimental colitis; TIPE2 is a negative regulator of antibacterial immunity, indicating that TIPE2 promotes colitis by inhibiting mucosal immunity to commensal bacteria.
TIPE2 plays a crucial atheroprotective role likely by regulating macrophage responses to oxidized low-density lipoprotein.
study reports that TIPE2, the tumor necrosis factor-alpha-induced protein 8-like 2, plays an atheroprotective role by regulating phenotypic switching of vascular smooth muscle cells in response to oxidized low-density lipoprotein stimuli
Acts as a negative regulator of innate and adaptive immunity by maintaining immune homeostasis. Negative regulator of Toll-like receptor and T-cell receptor function. Prevents hyperresponsiveness of the immune system and maintains immune homeostasis. Inhibits jun/ap1 and NF-kappa-B activation. Promotes Fas-induced apoptosis (By similarity).
TNF alpha-induced protein 8-like protein 2
, TNFAIP8-like protein 2
, inflammation factor 20
, inflammation factor protein 20
, tumor necrosis factor alpha-induced protein 8-like protein 2
, tumor necrosis factor, alpha-induced protein 8-like protein 2
, Tumor necrosis factor, alpha-induced protein 8-like protein 2
, tumor necrosis factor, alpha-induced protein 8-like protein 2 a